Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.18, Zacks reports. The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.03 million.
Inovio Pharmaceuticals Trading Down 1.0 %
NASDAQ:INO traded down $0.02 during trading hours on Friday, hitting $1.92. 2,019,265 shares of the company were exchanged, compared to its average volume of 550,681. The stock has a market capitalization of $50.11 million, a price-to-earnings ratio of -0.48 and a beta of 0.92. Inovio Pharmaceuticals has a one year low of $1.74 and a one year high of $14.75. The company has a fifty day simple moving average of $2.04 and a 200 day simple moving average of $3.71.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. JMP Securities reissued a "market outperform" rating and set a $18.00 price objective on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. Royal Bank of Canada cut their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a "sector perform" rating on the stock in a report on Wednesday. HC Wainwright reaffirmed a "neutral" rating and set a $3.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday. Finally, StockNews.com raised Inovio Pharmaceuticals to a "sell" rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $12.20.
Get Our Latest Analysis on Inovio Pharmaceuticals
Inovio Pharmaceuticals Company Profile
(
Get Free Report)
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Further Reading
Before you consider Inovio Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.
While Inovio Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
